Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H28N8 |
Molecular Weight | 416.522 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC1=NN(CC2=CN=C(C=C2)C3=CC=CC=C3C4=NN=NN4)C(CCCC)=N1
InChI
InChIKey=YONOBYIBNBCDSJ-UHFFFAOYSA-N
InChI=1S/C23H28N8/c1-3-5-11-21-25-22(12-6-4-2)31(28-21)16-17-13-14-20(24-15-17)18-9-7-8-10-19(18)23-26-29-30-27-23/h7-10,13-15H,3-6,11-12,16H2,1-2H3,(H,26,27,29,30)
Molecular Formula | C23H28N8 |
Molecular Weight | 416.522 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Forasartan (also known as SC-52458) was developed as an orally active, competitive angiotensin (Ang) II subtype 1 (AT1)-receptor antagonist for the treatment of hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. It is known that angiotensin II is a vasoconstrictor and stimulates the synthesis and release of aldosterone, and blockage of its effects results in a decrease in systemic vascular resistance. Information about the further development of forasartan is not available.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9156352
two groups of eight healthy men ingested placebo or increasing single oral doses (10, 25, and 50 mg or 100, 150, and 200 mg) of SC-52458 (FORASARTAN).
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:47:30 GMT 2023
by
admin
on
Fri Dec 15 15:47:30 GMT 2023
|
Record UNII |
065F7WPT0B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66930
Created by
admin on Fri Dec 15 15:47:30 GMT 2023 , Edited by admin on Fri Dec 15 15:47:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
145216-43-9
Created by
admin on Fri Dec 15 15:47:30 GMT 2023 , Edited by admin on Fri Dec 15 15:47:30 GMT 2023
|
PRIMARY | |||
|
132706
Created by
admin on Fri Dec 15 15:47:30 GMT 2023 , Edited by admin on Fri Dec 15 15:47:30 GMT 2023
|
PRIMARY | |||
|
DB01342
Created by
admin on Fri Dec 15 15:47:30 GMT 2023 , Edited by admin on Fri Dec 15 15:47:30 GMT 2023
|
PRIMARY | |||
|
141552
Created by
admin on Fri Dec 15 15:47:30 GMT 2023 , Edited by admin on Fri Dec 15 15:47:30 GMT 2023
|
PRIMARY | |||
|
100000080432
Created by
admin on Fri Dec 15 15:47:30 GMT 2023 , Edited by admin on Fri Dec 15 15:47:30 GMT 2023
|
PRIMARY | |||
|
7415
Created by
admin on Fri Dec 15 15:47:30 GMT 2023 , Edited by admin on Fri Dec 15 15:47:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL315021
Created by
admin on Fri Dec 15 15:47:30 GMT 2023 , Edited by admin on Fri Dec 15 15:47:30 GMT 2023
|
PRIMARY | |||
|
6896
Created by
admin on Fri Dec 15 15:47:30 GMT 2023 , Edited by admin on Fri Dec 15 15:47:30 GMT 2023
|
PRIMARY | |||
|
Forasartan
Created by
admin on Fri Dec 15 15:47:30 GMT 2023 , Edited by admin on Fri Dec 15 15:47:30 GMT 2023
|
PRIMARY | |||
|
SUB07781MIG
Created by
admin on Fri Dec 15 15:47:30 GMT 2023 , Edited by admin on Fri Dec 15 15:47:30 GMT 2023
|
PRIMARY | |||
|
C65749
Created by
admin on Fri Dec 15 15:47:30 GMT 2023 , Edited by admin on Fri Dec 15 15:47:30 GMT 2023
|
PRIMARY | |||
|
C084927
Created by
admin on Fri Dec 15 15:47:30 GMT 2023 , Edited by admin on Fri Dec 15 15:47:30 GMT 2023
|
PRIMARY | |||
|
065F7WPT0B
Created by
admin on Fri Dec 15 15:47:30 GMT 2023 , Edited by admin on Fri Dec 15 15:47:30 GMT 2023
|
PRIMARY | |||
|
GG-68
Created by
admin on Fri Dec 15 15:47:30 GMT 2023 , Edited by admin on Fri Dec 15 15:47:30 GMT 2023
|
PRIMARY | |||
|
DTXSID70162942
Created by
admin on Fri Dec 15 15:47:30 GMT 2023 , Edited by admin on Fri Dec 15 15:47:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|